Background
Women undergoing hysteroscopic myomectomy are prone to significant blood loss and hematological disturbances. Oxytocin is a uterotonic drug. Tranexamic acid has been used to reduce blood loss in many surgeries. The aim of our study was to compare between oxytocin and tranexamic acid as regard their safety and effectiveness on reducing perioperative blood loss and perioperative transfusion requirement during hysteroscopic myomectomy.
Methods
This study included 60 patients scheduled for hysteroscopic myomectomy allocated into 2 groups: group A: Patient received 10 mg/kg of tranexamic acid slowly intravenous after induction of anesthesia, group B: Patients received infusion of 10 IU of oxytocin at a rate of 400 mIU/min till the end of the procedure. Preoperative and postoperative hemoglobin and hematocrit, need for blood transfusion, duration of operation, complications and medications’ side effects were recorded.
Results
The 2 groups were comparable in terms of mean difference between preoperative and postoperative hemoglobin an hematocrit, operative time, operative complication and medications’ adverse effects. No patient needed any blood component transfusion in both groups.
Conclusions
We concluded that tranexamic acid and oxytocin are equally effective in reducing blood loss and transfusion requirements in hysteroscopic myomectomy with good safety profile. Both of them can be used according to the availability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.